The Israeli pharmaceutical company, which specializes in generic drugs, is riding a wave of expiring patents to big profits.
Teva (TEVA) is expected to reap billions of dollars in sales from generic versions of drugs that will lose patent protection through 2013. This could spark a boom in demand for cheap medicines in emerging markets such as China, Russia and India.
But the company also develops and sells its own pharmaceuticals, including one of the world's leading MS drugs, Copaxone.
Ironically, Copaxone could face the threat of generic competition when its patent expires in 2014. But Teva has a broad product pipeline, with 15 drugs in late-stage clinical trials.
The cash-rich company has been on a buying spree. It recently bought the third-largest generic drug maker in Japan, giving it access to the second largest global pharmaceutical market.
The crisis in Europe will continue, but Japan will bounce back in the second half of the year say fund managers David Katz and Paul Dietrich. More
A reality check for oil and gold. Prices may have peaked. But a little patience goes a long way. Emerging market demand is likely to keep prices from falling too far. More
Global turmoil persists